Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B

Journal of Hepatology

Volumn 32, Issue 2, 2000, Pages 307-316

  Pichoud, Christian ^a   Berby, Françoise ^a   Stuyver, Lieven ^c   Petit, Marie Anne ^d   Trépo, Christian ^a,b   Zoulim, Fabien ^a,b  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c INNOGENETICS   (Belgium)

^d HÔPITAL PAUL BROUSSE   (France)

Author keywords

Antiviral therpay; Hepatitis B virus; Immune response; Pre core mutants; Viral resistance

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; FAMCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DNA DETERMINATION; GENE MUTATION; HEPATITIS B; HUMAN; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROCONVERSION; VIREMIA; VIRUS REPLICATION;

EID: 0033967714     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80077-X     Document Type: Article

References (41)

1. Lee WM. Hepatitis B virus infection. N Engl J Med. 337:1997;1733-1745.
2. Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the healthy HBs Ag carrier state. Hepatology. 7:1987;758-763.
3. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 336:1997;347-356.
4. Günther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occuring variants of hepatitis B virus. Adv Virus Res. 52:1999;25-137.
5. Carman W, Hadziyannis S, Mc Garvey MJ, Jacyna M, Karayiannis P, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. ii:1989;588-591.
6. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol. 64:1990;1298-1303.
7. Tong S, Li J, Vivitski L, Trépo C. Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology. 176:1990;596-603.
8. Lok A, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pregenome encapsidation signal. Proc Natl Acad Sci USA. 91:1994;4077-4081.
9. Buckwold VE, Xu Z, Chen M, Yen TSB, Ou J-H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol. 70:1996;5845-5851.
10. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol. 68:1994;8102-8110.
11. Günther S, Piwon N, Iwanska A, Schilling R, Meisel H, Will H. Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol. 70:1996;8318-8331.
12. Günther S, Paulij W, Meisel H, Will H. Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity. Virology. 244:1998;146-160.
13. Fattovich G, Brollo L, Alberti A, Ponisso P, Giustina G, Realdi G. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology. 8:1988;1651-1654.
14. Brunetto M, Giarin M, Oliveri F, Chiaberge E, Baldi M, Alfarano A, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA. 88:1991;4186-4190.
15. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trépo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol. 48:1996;8-16.
16. Lok ASF, Akarca US, Greene S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology. 21:1995;19-24.
17. Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology. 29:1999;976-984.
18. Lai CL, Chine RW, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med. 339:1998;61-68.
19. Nowak M, Bonhoeffer S, Hill A, Boehme R, Thomas H, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA. 93:1996;4398-4402.
20. Zoulim F, Trépo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol. 29:1998;151-168.
21. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrell DLJ, et al. Identification and characterization of mutations in hepatitis B virus resistant to Lamivudine. Hepatology. 27:1998;1670-1677.
22. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol. 1997;1148-1153.
23. Locarnini SA, Aye TT, Shaw T, De Man R, Angus PW, McCaughan GW, et al. The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy following liver transplantation. Hepatology. 26:((N04 Pt2)):1997;. abstract 958.
24. de Man RA, Bartholomeusz AI, Niesters HGM, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol. 29:1998;669-675.
25. Habersetzer F, Zoulim F, Jusot JF, Zhang X, Trabaud MA, Chevallier P, et al. Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon alpha. J Viral Hepatitis. 5:1998;407-414.
26. Zaaijer H, ter Borg F, Cuypers H, Hermus M, Lelie P. Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol. 32:1994;2088-2091.
27. Kessler HH, Pierer K, Dragon E, Lackner H, Santner B, Stünzer D, et al. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. Clin Diagn Virol. 9:1998;37-43.
28. Gerken G, Gomes J, Lampertico P, Colombo M, Rothaar T, Trippler M, et al. Clinical evaluation and applications of the amplicor HBV monitorTM test, a quantitative HBV DNA PCR assay. J Virol Methods. 74:1998;155-165.
29. Petit M, Zoulim F, Berthillon P, Capel F, Li J, Dauguet C, et al. PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B. J Hepatol. 20:1994;47-56.
30. Petit M, Zoulim F, Capel F, Dubanchet S, Dauguet C, Trépo C. Variable expression of pre-S1 antigen in serum during chronic hepatitis B virus infection: an accurate marker for the level of hepatitis B virus replication. Hepatology. 11:1990;809-814.
31. Stuyver L, Wyseur L, van Arnhem W, Hernandez F, Maertens G. A second generation line probe assay for hepatitis C virus. J Clin Microbiol. 34:1996;2259-2266.
32. Van Geyt C, De Gendt S, Rombout A, Wyseur A, Maertens G, Rossau R, et al. A line probe assay for hepatitis B virus genotypes. In: Schinazi RFS, Sommadossi J-P, Thomas HC, editors. Therapies for Viral Hepatitis. London: International Medical Press. p. 139-45.
33. Pichoud C, Seignères B, Wang Z, Trepo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology. 29:1999;230-237.
34. Perillo R, Schiff E, Davis G, Bodenheimer HC, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 323:1990;295-301.
35. Trépo C, Jezek P, Atkinson G, Boon R. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study. Hepatology. 24:(188A):1996;. (abstract 247).
36. Butterworth LA, Prior SL, Buda PJ, Faoagali JL, Cooksley WG. Comparison of four methods for quantitative measurement of hepatitis B viral DNA. J Hepatol. 24:1996;686-691.
37. Zoulim F, Mimms L, Floreani M, Pichoud C, Chemin I, Kay A, et al. New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection. J Clin Microbiol. 30:1992;1111-1119.
38. Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, et al. Rapid detection of mutations in the promoter and the pre-core region of HBV genome: correlation with viral persistence and disease activity. Hepatology. 28:((4 (pt2))):1998;. abstract 294.
39. Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology. 86:1984;230-235.
40. Honkoop P, De Man RA, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet. 346:1995;1156-1157.
41. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a six month randomized dose-ranging study. Gastroenterology. 113:1997;1258-1263.